Date: 2017-09-27
Type of information: Licensing agreement
Compound: CDK11 inhibitor payload series for the development of antibody drug conjugates
Company: Cancer Research UK (CRUK) (UK) Glythera (UK)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: payload series for antibody drug conjugates (ADC)
Disease:
Details:
- • On September 26, 2017, Glythera, a next generation antibody drug conjugate (ADC) development company, and Cancer Research UK announced an agreement giving Glythera exclusive, worldwide rights to the charity’s novel CDK11 inhibitor payload series for the development of multiple ADCs conjugated using Glythera’s proprietary PermaLink® conjugation platform.
- According to the agreement, Glythera and Cancer Research UK will select and optimise toxins from the inhibitor payload series for development in ADCs. Glythera will then progress multiple ADCs, optimised according to cancer cell-kill profiles, for difficult-to-treat tumours. Glythera is currently evaluating a range of clinically important antibody targets and intends to identify its first clinical ADC candidate by 2019.
- The CDK11 inhibitor programme has identified a series of low molecular weight, synthetically tractable compounds which potently inhibit and are selective against other kinase targets. The series demonstrates highly potent anti-proliferative activity in dividing and non-dividing tumour cells and represents an exciting approach for ADCs.
Financial terms:
- Under the Terms of the agreement, Cancer Research UK will receive an undisclosed up-front fee, milestone payments on programme success for each resulting ADC, and royalties on worldwide product sales. Glythera is responsible for the development, manufacturing and commercialisation of any ADC products resulting from the agreement.
Latest news:
Is general: Yes
